Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments

INTRODUCTION: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and their associated costs and effects in daily clinical practice. We estimated the real-wor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: De Groot, S., Blommestein, H. M., Redekop, W. K., Sleijfer, S., Kiemeney, L. A. L. M., Oosterwijk, E., Uyl-de Groot, C. A.
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2017
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5439671/
https://ncbi.nlm.nih.gov/pubmed/28531203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177364
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Chargement en cours...

Documents similaires